Leis-Filho Antonio Fernando, Lainetti Patrícia de Faria, Franzoni Mayara Simão, Palmieri Chiara, Kobayshi Priscila Emiko, Laufer-Amorim Renee, Fonseca-Alves Carlos Eduardo
Department of Veterinary Surgery and Animal Reproduction, Sao Paulo State University-UNESP, Botucatu 18618-681, Brazil.
School of Veterinary Science, Gatton Campus, The University of Queensland-UQ, Brisbane Qld 4343, Australia.
J Pers Med. 2021 Mar 23;11(3):232. doi: 10.3390/jpm11030232.
CD24 is a cell surface molecule anchored by glycosyl-phosphatidyl-inositol and expressed by different human cancers, including prostate cancer (PC). Some studies have demonstrated that CD24 expression is associated with poor patient outcome; however, few studies have investigated CD24 expression in spontaneous animal models of human PC, such as canine PC. This study aimed to evaluate the expression of CD24 in human PC using the in silico analysis of the data obtained from The Cancer Genome Atlas (TCGA) and comparing it with the previously published prostatic canine transcriptome data. In addition, CD24 expression was confirmed by immunohistochemistry in an independent cohort of canine prostatic samples and its prognostic significance assessed. The systematic review identified 10 publications fitting with the inclusion criteria of this study. Of the 10 manuscripts, 5 demonstrated a direct correlation between CD24 overexpression and patient prognoses. CD24 expression was also associated with PSA relapse (2/5) and tumor progression (1/5). However, the in silico analysis did not validate CD24 as a prognostic factor of human PC. Regarding canine PC, 10 out of 30 normal prostates and 27 out of 40 PC samples were positive for CD24. As in humans, there was no association with overall survival. Overall, our results demonstrated a significant CD24 overexpression in human and canine prostate cancer, although its prognostic value may be questionable. However, tumors overexpressing CD24 may be a reliable model for new target therapies and dogs could be used of a unique preclinical model for these studies.
CD24是一种通过糖基磷脂酰肌醇锚定在细胞表面的分子，在包括前列腺癌（PC）在内的多种人类癌症中均有表达。一些研究表明，CD24的表达与患者预后不良相关；然而，很少有研究在人类PC的自发动物模型（如犬类PC）中研究CD24的表达。本研究旨在通过对从癌症基因组图谱（TCGA）获得的数据进行计算机分析，并将其与先前发表的前列腺犬转录组数据进行比较，来评估CD24在人类PC中的表达。此外，通过免疫组织化学在一组独立的犬前列腺样本中证实了CD24的表达，并评估了其预后意义。系统评价确定了10篇符合本研究纳入标准的出版物。在这10篇手稿中，有5篇表明CD24过表达与患者预后之间存在直接关联。CD24的表达还与前列腺特异性抗原（PSA）复发（2/5）和肿瘤进展（1/5）有关。然而，计算机分析并未验证CD24作为人类PC预后因素的作用。关于犬类PC，30个正常前列腺中有10个，40个PC样本中有27个CD24呈阳性。与人类一样，CD24与总生存期无关。总体而言，我们的结果表明，CD24在人类和犬类前列腺癌中均有显著过表达，尽管其预后价值可能存在疑问。然而，过表达CD24的肿瘤可能是新靶向治疗的可靠模型，犬类可作为这些研究的独特临床前模型。
